GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Therapeutic Solutions International Inc (OTCPK:TSOI) » Definitions » Piotroski F-Score

Therapeutic Solutions International (Therapeutic Solutions International) Piotroski F-Score : 3 (As of May. 06, 2024)


View and export this data going back to 2008. Start your Free Trial

What is Therapeutic Solutions International Piotroski F-Score?

Warning Sign:

Piotroski F-Score of 3 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Therapeutic Solutions International has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for Therapeutic Solutions International's Piotroski F-Score or its related term are showing as below:

TSOI' s Piotroski F-Score Range Over the Past 10 Years
Min: 3   Med: 3   Max: 5
Current: 3

During the past 13 years, the highest Piotroski F-Score of Therapeutic Solutions International was 5. The lowest was 3. And the median was 3.


Therapeutic Solutions International Piotroski F-Score Historical Data

The historical data trend for Therapeutic Solutions International's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Therapeutic Solutions International Piotroski F-Score Chart

Therapeutic Solutions International Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.00 4.00 5.00 3.00 3.00

Therapeutic Solutions International Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.00 2.00 2.00 2.00 3.00

Competitive Comparison of Therapeutic Solutions International's Piotroski F-Score

For the Biotechnology subindustry, Therapeutic Solutions International's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Therapeutic Solutions International's Piotroski F-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Therapeutic Solutions International's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Therapeutic Solutions International's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Net Income was -0.578 + -0.562 + -0.602 + -0.427 = $-2.17 Mil.
Cash Flow from Operations was -0.201 + -0.337 + -0.311 + -0.206 = $-1.06 Mil.
Revenue was 0.023 + 0.026 + 0.026 + 0.024 = $0.10 Mil.
Gross Profit was 0.015 + 0.016 + 0.019 + 0.013 = $0.06 Mil.
Average Total Assets from the begining of this year (Dec22)
to the end of this year (Dec23) was
(3.606 + 3.55 + 3.487 + 3.474 + 3.292) / 5 = $3.4818 Mil.
Total Assets at the begining of this year (Dec22) was $3.61 Mil.
Long-Term Debt & Capital Lease Obligation was $0.11 Mil.
Total Current Assets was $0.09 Mil.
Total Current Liabilities was $1.90 Mil.
Net Income was -0.601 + -1.191 + -0.946 + -1.076 = $-3.81 Mil.

Revenue was 0.085 + 0.039 + 0.075 + 0.009 = $0.21 Mil.
Gross Profit was 0.069 + 0.03 + 0.066 + -0.037 = $0.13 Mil.
Average Total Assets from the begining of last year (Dec21)
to the end of last year (Dec22) was
(1.716 + 4.781 + 4.541 + 4.192 + 3.606) / 5 = $3.7672 Mil.
Total Assets at the begining of last year (Dec21) was $1.72 Mil.
Long-Term Debt & Capital Lease Obligation was $0.01 Mil.
Total Current Assets was $0.31 Mil.
Total Current Liabilities was $2.21 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Therapeutic Solutions International's current Net Income (TTM) was -2.17. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Therapeutic Solutions International's current Cash Flow from Operations (TTM) was -1.06. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec22)
=-2.169/3.606
=-0.6014975

ROA (Last Year)=Net Income/Total Assets (Dec21)
=-3.814/1.716
=-2.22261072

Therapeutic Solutions International's return on assets of this year was -0.6014975. Therapeutic Solutions International's return on assets of last year was -2.22261072. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Therapeutic Solutions International's current Net Income (TTM) was -2.17. Therapeutic Solutions International's current Cash Flow from Operations (TTM) was -1.06. ==> -1.06 > -2.17 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec22 to Dec23
=0.111/3.4818
=0.03188006

Gearing (Last Year: Dec22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec21 to Dec22
=0.011/3.7672
=0.00291994

Therapeutic Solutions International's gearing of this year was 0.03188006. Therapeutic Solutions International's gearing of last year was 0.00291994. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec23)=Total Current Assets/Total Current Liabilities
=0.086/1.9
=0.04526316

Current Ratio (Last Year: Dec22)=Total Current Assets/Total Current Liabilities
=0.31/2.21
=0.14027149

Therapeutic Solutions International's current ratio of this year was 0.04526316. Therapeutic Solutions International's current ratio of last year was 0.14027149. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Therapeutic Solutions International's number of shares in issue this year was 3713.223. Therapeutic Solutions International's number of shares in issue last year was 2608.902. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=0.063/0.099
=0.63636364

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=0.128/0.208
=0.61538462

Therapeutic Solutions International's gross margin of this year was 0.63636364. Therapeutic Solutions International's gross margin of last year was 0.61538462. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec22)
=0.099/3.606
=0.02745424

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec21)
=0.208/1.716
=0.12121212

Therapeutic Solutions International's asset turnover of this year was 0.02745424. Therapeutic Solutions International's asset turnover of last year was 0.12121212. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+1+1+0+0+0+1+0
=3

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Therapeutic Solutions International has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

Therapeutic Solutions International  (OTCPK:TSOI) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Therapeutic Solutions International Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Therapeutic Solutions International's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Therapeutic Solutions International (Therapeutic Solutions International) Business Description

Traded in Other Exchanges
N/A
Address
701 Wild Rose Lane, Elk City, ID, USA, 83525
Therapeutic Solutions International Inc focuses on immune modulation for the treatment of several specific diseases. It is engaged in developing a range of immune-modulatory agents to target certain cancers, improve maternal and fetal health, fight periodontal disease, and for daily health. The business divisions of the company are Nutraceutical Division which produces nutraceuticals. Its current product, QuadraMune, is a patented synergistic blend of pterostilbene, sulforaphane, epigallocatechingallate, and thymoquionone. Cellular Division obtained exclusive rights to a patented adult stem cell for the development of therapeutics in the area of chronic traumatic encephalopathy (CTE) and traumatic brain injury (TBI) and Lung Pathology (LP).
Executives
Thomas Ichim director 211 E. OSBORN RD, PHOENIX AZ 85012
Gerry B Berg officer: CFO 1658 AVENIDA LA POSTA, ENCINITAS CA 92024
Timothy G Dixon director, officer: Chairman, President, CEO 4093 OCEANSIDE BLVD., SUITE B, OCEANSIDE CA 92056
Barry Glassman officer: VP, Training & Education 2051 ELBOW LANE, ALLENTOWN PA 18103
James P Boyd director, 10 percent owner PO BOX 2145, RANCHO SANTA FE CA 92067

Therapeutic Solutions International (Therapeutic Solutions International) Headlines

From GuruFocus